368 related articles for article (PubMed ID: 31142382)
1. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
2. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
Front Immunol; 2021; 12():653081. PubMed ID: 33936075
[TBL] [Abstract][Full Text] [Related]
3. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
4. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
5. Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
Kaidun P; Holzmayer SJ; Greiner SM; Seller A; Tegeler CM; Hagelstein I; Mauermann J; Engler T; Koch A; Hartkopf AD; Salih HR; Märklin M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685962
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
[TBL] [Abstract][Full Text] [Related]
8. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
9. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
10. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
12. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
14. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
15. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
16. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
[TBL] [Abstract][Full Text] [Related]
17. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
19. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
20. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Paczulla AM; Rothfelder K; Raffel S; Konantz M; Steinbacher J; Wang H; Tandler C; Mbarga M; Schaefer T; Falcone M; Nievergall E; Dörfel D; Hanns P; Passweg JR; Lutz C; Schwaller J; Zeiser R; Blazar BR; Caligiuri MA; Dirnhofer S; Lundberg P; Kanz L; Quintanilla-Martinez L; Steinle A; Trumpp A; Salih HR; Lengerke C
Nature; 2019 Aug; 572(7768):254-259. PubMed ID: 31316209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]